Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı.
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Trombositler birçok kardiyovasküler olayda merkezi role sahiptirler.
📊
Temel Bulgular & Veri:Tirofiban, trombosit agregasyonunu önleyen bir glikoprotein (GP) Ilb/IIIa reseptör inhibitörüdür.
💡
Sonuç & Katkı:Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Özet
Trombositler birçok kardiyovasküler olayda merkezi role sahiptirler. Tirofiban, trombosit agregasyonunu önleyen bir glikoprotein (GP) Ilb/IIIa reseptör inhibitörüdür. Bu olguda tirofiban tedavisi sonrası gelişen trombositopeni ve trombositopeni yapan diğer nedenlerin gözden geçirilmesi amaçlandı.
Abstract
Platelets have a central role in many cardiovascular events. Tirofiban is a glycoprotein (GP) IIb/IIIa receptor inhibitor that prevents platelet aggregation. In this report, it was aimed to review the thrombocytopenia induced by tirofiban treatment and other causes of thrombocytopenia.
🔖
Bu Makaleye Atıf Yap
AÇIKGÖZ, N., PAKDEMİR, H., ÖZDEMİR, R., CANSEL, M., YAĞMUR, J., ERMİŞ, N. (2022). Tirofiban tedavisi sonrası gelişen trombositopeni olgusu. İnönü Üniversitesi Tıp Fakültesi Dergisi, Cilt: 17 - Sayı: 1, 55–57. https://ajindex.com/articles/548518
Boersma E, Harrington EA, Molitemo DJ, White H, Simoons ML. Platelet glycoprotein Ilb/IIIa inhibitors in acute coronary syndromes: a metaanalysis of all major randomised clinical trials. Lancet 2002;359(9302):189-98
Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein Ilb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003;41:26-32
Özmen F, Atalar E, Özer N. Akut koroner sendromda trombositler ve glikoprotein Ilb/IIIa inhibitörleri. Türk J Cardiol 2007;10:91-100
Abrams CS, Cines DB. Thrombocytopenia after treatment with platelet glycoprotein Ilb/IIIa inhibitors. Curr Hematol Rep 2004;3:143-47
Aster RH. Drug-induced immune thrombocytopenia: an overview of pathogenesis. Semin Hematol 1999;362-66
Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT and antiphospholipid syndrome. Hematology 2003;497-519
Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, Lind RN, Pereira J, Aster RH. Acute thrombocytopenia after treatment with tirofiban or eptifibatide Thrombocytopenia after tirofiban is associated with antibodies specific for ligand- occupied GPIIb/IIIa. Blood 2002;100:2071-6
Curtis B, Swyers J, D ivgi A, McFarland J, Aster R. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab coated platelets. Blood 2002;99:2054-9
Eryonucu B, Tuncer M, Erkoc R. Repetitive profound thrombocytopenia after treatment with tirofiban: a case report. Cardiovasc Drugs Therapy 2004;18:503-5
Demirkan B, Guray Y, Guray U, Korkmaz S. Differential diagnosis and management of acute profound thrombocytopenia by tirofiban: a case report, J Thromb Thrombolysis 2006;22:77-8
Beiras-Fernandez A, Kowert A, Jiru P, Weis M, Spannagl M, Reichart B, Schmoeckel M. Acute profound thrombocytopenia after treatment with tirofiban and off-pump coronary artery bypass grafting. Ann Thorac Surg 2009;87(2):629-31.